Amarin (NASDAQ:AMRN) Q3 results:
Revenues: $112.4M (+103.3%); product sales: $112.3M (+104.2%).
Net loss: ($3.5M) (+85.7%); non-GAAP net income: $4.5M (+125.3%); loss/share: ($0.01) (+87.5%); non-GAAP EPS: $0.01 (+116.7%).
Per IQVIA, 787K Vascepa prescriptions filled (+88.7%).
Ad Com meeting November 14 for Vascepa CV benefit claim. FDA action date December 28.
Salesforce to grow to ~800 at start of 2020.
2019 guidance: Revenue: $380M – 420M (unch).
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.